SLU-PP-332: The "Exercise Mimetic" Compound Explained
SLU-PP-332 is a synthetic ERR agonist that switches on the metabolic gene program of endurance exercise, at least in mice. It is marketed as an exercise mimetic and sold alongside research peptides, though it is not a peptide and has no human data behind it. Here is what the science shows and what it does not.
What Is SLU-PP-332?
SLU-PP-332 is a small synthetic molecule developed by researchers at Saint Louis University as an agonist of the estrogen-related receptors. It drew attention because mice given the compound showed the metabolic hallmarks of endurance training, more energy burned and more fat oxidized, without running any further than usual.
That single result, an exercise-like effect from a pill, is why the compound spread through fitness and longevity circles. It is now sold by the same vendors that handle research peptides, which is how it picked up the peptide label it does not deserve.
Why It Is Not Actually a Peptide
A peptide is a short chain of amino acids linked by peptide bonds. SLU-PP-332 has neither. It is a small-molecule drug candidate, structurally closer to a conventional pharmaceutical than to BPC-157 or a GLP-1 agonist.
The peptide label is marketing, not chemistry. It sits beside compounds like MK-677, RAD-140, and turkesterone, non-peptide research chemicals that share a marketplace and an audience but not a molecular class. Keeping that distinction straight matters because the safety questions differ by class.
How It Works: The ERR Pathway
The estrogen-related receptors (ERR alpha, beta, and gamma) are nuclear receptors that regulate genes controlling mitochondrial biogenesis, fatty acid oxidation, and cellular respiration. Endurance exercise activates this same network, which is how training builds aerobic capacity over time.
SLU-PP-332 activates these receptors directly. In doing so it turns on the downstream genes pharmacologically rather than through physical work. The result in animals is a metabolic state that looks, at the level of gene expression and energy use, like the aftermath of exercise. For background on receptor-driven signaling, see peptide hormones.
What the Research Shows
In rodent studies, SLU-PP-332 raised whole-body energy expenditure, increased fatty acid oxidation, improved running endurance, reduced fat mass accumulation, and improved insulin sensitivity in models of metabolic syndrome. Later medicinal-chemistry work dissected the molecule to identify which structural features drive ERR activity, groundwork for optimizing the scaffold.
Read that list with the qualifier attached: every finding is preclinical, in mice and in cell-based assays. Impressive animal metabolic results are common and frequently fail to translate to humans. The compound is a legitimate research lead, not a validated therapy.
The Human Evidence Gap
There are no published human clinical trials of SLU-PP-332 as of 2026. No human dose, no human safety data, no human efficacy data. Any dosing protocol you find online is extrapolated from milligram-per-kilogram mouse studies, a conversion that is unreliable and ignores species differences in receptor distribution and metabolism.
This is the same evidence problem that runs through much of the research compound market: promising mechanism, no human validation, sold anyway. The pattern is worth recognizing because it recurs with almost every new compound that trends.
Safety and Unknowns
Without human trials, SLU-PP-332 has no established safety profile. The ERR receptors it targets are expressed across many tissues, including the heart, so broad pharmacological activation could produce effects far from the intended fat-metabolism benefit. None of that has been characterized in people.
On top of the biological uncertainty sits a supply problem. Material is sold as unregulated research chemical with no purity testing, no dose verification, and frequent mislabeling. The combined risk, unknown biology plus unknown product quality, is covered in gray-market risks and peptide testing and quality.
Legal and Regulatory Status
SLU-PP-332 is not FDA approved for any use and is not classified as a dietary supplement. It is sold as a research chemical, typically labeled not for human consumption, which is the standard disclaimer that lets vendors operate. Purchasing it for personal use places you in the same unregulated channel discussed in are peptides legal.
It is not affected by the 2026 FDA peptide reclassification, since that process concerns specific compounding-list peptides, not small molecules like this one. See the FDA peptide category update for what that change does and does not cover.
Can It Replace Exercise?
No, and the framing oversells it. SLU-PP-332 reproduces one slice of exercise biology, the metabolic gene signature, in animals. Real exercise also strengthens the heart, builds muscle and bone, sharpens cognition, and lifts mood through pathways a single receptor agonist does not engage.
The most it could plausibly become, if human trials ever confirm the animal work, is a metabolic adjunct for people who cannot exercise, not a shortcut around training. Until those trials exist, it is a research compound with an appealing story and no proof in humans. For the broader category, see growth hormone peptides and peptides for fat loss.
Related Guides
Research Peptides
How the gray market for research compounds works and where the risks sit.
MK-677
Another non-peptide research compound sold in the same market.
Peptides for Fat Loss
The wider landscape of compounds marketed for metabolism and fat loss.
Gray-Market Risks
What you are actually buying when a product says research only.
Turkesterone
A popular performance supplement with a similar evidence problem.
What Are Peptides?
The chemistry that separates real peptides from small molecules.
Frequently Asked Questions About SLU-PP-332
SLU-PP-332 is a synthetic small-molecule agonist of the estrogen-related receptors (ERR alpha, beta, and gamma), developed by researchers at Saint Louis University. In mice it switches on the same gene program that endurance exercise activates, which is why it is described as an exercise mimetic. It is a research compound, not an approved drug or supplement.
No. Despite being sold under peptide-style branding, SLU-PP-332 is a small synthetic molecule, not a peptide. It contains no chain of amino acids. It gets grouped with research peptides because it is sold through the same gray-market vendors and marketed to the same fitness and longevity audience, but chemically it belongs to a different class entirely.
It binds and activates the estrogen-related receptors, a family of nuclear receptors that control genes for mitochondrial biogenesis, fatty acid oxidation, and cellular respiration. This is the transcriptional program that endurance training normally turns on. By activating it pharmacologically, SLU-PP-332 produced higher energy expenditure and fat oxidation in mice without the animals doing any extra exercise.
In rodent studies, SLU-PP-332 increased energy expenditure, raised fatty acid oxidation, improved running endurance, reduced fat mass, and improved insulin sensitivity in models of metabolic syndrome. Follow-up chemistry work mapped the structural features that drive its receptor activity. All of this is preclinical. The findings are in mice and cell assays, not people.
No published human clinical trials exist as of 2026. There is no human data on effective dose, safety, side effects, or long-term consequences. Everything circulating about human dosing is extrapolated from animal studies, which is not a reliable basis for taking a compound. The absence of human data is the single most important fact about it.
Unknown, and that is the honest answer. Without human trials there is no established safety profile. ERR receptors are expressed widely, including in the heart, so systemic activation could have effects well beyond fat metabolism that have not been characterized in people. Material sold online is unregulated research chemical with no purity guarantee, compounding the uncertainty.
It is not approved by the FDA for any use and is not a dietary supplement. It is sold as a research chemical, usually labeled not for human consumption. Buying it for personal use sits in the same unregulated gray market as other research compounds, with the same problems around quality control, mislabeling, and contamination.
No. It reproduces part of the metabolic gene signature of endurance exercise in mice, but exercise affects the cardiovascular system, musculoskeletal system, brain, and mood through mechanisms a single receptor agonist does not touch. Even in the best case it would be a partial metabolic tool, not a substitute for training. In humans, none of that is yet demonstrated.